Insmed Inc

Insmed Incorporated is a global biopharmaceutical company that develops and commercializes therapies for serious, chronic diseases. It has two approved products.

- **BRINSUPRI (brensocatib):** a once-daily oral reversible DPP1 inhibitor for non-cystic fibrosis bronchiectasis in patients aged 12 and older. It is approved in the U.S., EU, UK and Japan, and launched in Japan in October 2026.
- **ARIKAYCE (amikacin liposome inhalation suspension):** a once-daily inhaled liposomal antibiotic for refractory Mycobacterium avium complex (MAC) lung disease. It uses Insmed's PULMOVANCE liposomal technology and PARI's Lamira Nebulizer, and is approved in the U.S., Europe and Japan. An sNDA to expand the U.S. label to all MAC lung disease patients is under FDA Priority Review.

The company sells primarily in the United States, with growing international revenue from Europe and Japan. Its pipeline is organized into three therapeutic areas:

- **Respiratory:** TPIP (treprostinil palmitil inhalation powder), in Phase 3 for PH-ILD, PAH and PPF, with an IPF study planned. INS1148, an anti-SCF248 monoclonal antibody, is being developed for IPF.
- **Immunology & Inflammation:** INS1033, a DPP1 inhibitor for rheumatoid arthritis, followed by UC and COPD.
- **Neuro & Other Rare:** intrathecal AAV9 gene therapies INS1201 for Duchenne muscular dystrophy and INS1202 for ALS.

Its research engine spans gene therapy, AI-driven protein engineering, RNA end-joining and synthetic rescue. Financing includes a Pharmakon senior secured loan and an OrbiMed royalty financing. Updated Oct 29, 2026